Raily Aesthetic Medicine International Holdings Limited 瑞麗醫美國際控股有限公司 （於開曼群島註冊成立的有限公司） 附註： C 相關董事委員會的主席 執行董事 傅海曙先生 （董事會主席） 宋建良先生 （行政總裁） 王瀛先生 獨立非執行董事 林海博士 楊小芬女士 劉騰先生 | | 董事委員會 | | | | | --- | --- | --- | --- | --- | | 董事 | 審核委員會 薪酬委員會 | | 提名委員會 | 戰略 投資委員會 | | 傅海曙先生 | | M | C | C | | 宋建良先生 | | | | | | 王瀛先生 | | | | | | 林海博士 | M | C | M | M | | 楊小芬女士 | M | | M | M | | 劉騰先生 | C | M | | | 董事會設立四個委員會。下表載列各董事於該等委員會中所擔任的職位資料。 （股份代號：2135） 董事名單與其角色和職能 瑞麗醫美國際控股有限公司的董事（「董事」）會（「董事會」）成員載列如下： M 相關董事委員會的成員 中華人民共和國杭州，2026年3月2 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Raily Aesthetic Medicine International Holdings Limited 瑞麗醫美國際控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2135） 更換獨立非執行董事 及 董事委員會組成變動 瑞麗醫美國際控股有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，林 海博士（「林博士」）已獲委任為本公司獨立非執行董事，自2026年3月27日起生效。 董事會進一步宣佈，曹德全先生（「曹先生」）已辭任獨立非執行董事，自2026年3 月27日起生效。曹先生辭任後將不再擔任本公司任何職務，即時生效。 (1) 委任獨立非執行董事及董事委員會組成變動 董事會欣然宣佈，自2026年3月27日起，林博士已獲委任為本公司獨立非執行 董事、薪酬委員會主席、審核委員會成員、提名委員會成員及戰略投資委員會 成員。 林博士，43歲，現任四川大學生物醫學工程學院及國家生物醫學材料工 ...

Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 189,411,000, a decrease of 4.9% from RMB 199,342,000 in 2024[4] - Gross profit increased to RMB 77,711,000, up 8.9% from RMB 71,407,000 in the previous year[4] - The company reported a net loss of RMB 2,197,000 for the year, significantly improved from a loss of RMB 63,263,000 in 2024[4] - Basic and diluted earnings per share for the year were RMB 0.34, compared to a loss of RMB 11.11 per share in 2024[4] - The company reported a total loss before tax of RMB 65,257,000 for the year ending December 31, 2024, with significant contributions from unallocated expenses of RMB 25,798,000 and financial costs of RMB 584,000[23] - The pre-tax profit for 2025 was RMB 10,000, a recovery from a loss of RMB 65,257,000 in 2024[30] - The company reported a net profit of approximately RMB 1.9 million for 2025, compared to a net loss of approximately RMB 59.2 million in 2024, indicating a turnaround from loss to profit[39] - The total comprehensive loss for 2025 was approximately RMB 2.2 million, a significant improvement from a loss of RMB 63.3 million in 2024[76] Revenue Breakdown - For the year ending December 31, 2025, total revenue reached RMB 189,411,000, with medical beauty services contributing RMB 152,909,000, medical beauty equipment RMB 32,832,000, and consulting services RMB 3,670,000[24] - Revenue for the year ended December 31, 2025, was RMB 189,411 thousand, a decrease of 5.0% compared to RMB 199,342 thousand in 2024[49] - Revenue from medical beauty services in 2025 was approximately RMB 152.9 million, an increase of about 7.6% from RMB 142.1 million in 2024[60] - Revenue from minimally invasive beauty services in 2025 was approximately RMB 84.5 million, up about 23.4% from RMB 68.5 million in 2024, driven by an increase in active customers and average spending[60] - Revenue from skin beauty services in 2025 was approximately RMB 62.3 million, a decrease of about 8.4% from RMB 68.1 million in 2024, primarily due to a reduction in active customers[60] - Revenue from cosmetic surgery services in 2025 was approximately RMB 4.8 million, an increase from RMB 4.1 million in 2024[60] Expenses and Costs - Research and development expenses rose to RMB 2,070,000, an increase from RMB 717,000 in the previous year[4] - The cost of supplies consumed decreased to RMB 61,290,000 in 2025 from RMB 65,611,000 in 2024, suggesting improved cost efficiency[27] - Sales and distribution expenses in 2025 were approximately RMB 37.8 million, down about 20.8% from RMB 47.7 million in 2024, attributed to reduced market investments[72] - Administrative expenses decreased by approximately 25.1% to RMB 31.3 million in 2025, primarily due to a reduction in share-based payment expenses and intermediary service costs[73] - The financial cost for 2025 was approximately RMB 2.7 million, slightly down from RMB 2.8 million in 2024[74] Assets and Liabilities - Cash and cash equivalents increased to RMB 57,793,000, up from RMB 28,870,000 in 2024[5] - Total current liabilities amounted to RMB 125,755,000, slightly up from RMB 123,588,000 in 2024[5] - Non-current liabilities decreased significantly to RMB 13,638,000 from RMB 30,817,000 in the previous year[6] - The company's total assets less current liabilities stood at RMB 111,896,000, down from RMB 126,335,000 in 2024[5] - The company maintained a net asset value of RMB 98,258,000, an increase from RMB 95,518,000 in 2024[6] - The total liabilities as of December 31, 2025, were approximately RMB 139.4 million, down from RMB 154.4 million in 2024, resulting in a debt-to-equity ratio of approximately 141.8%[86] Shareholder Information - The company did not declare or pay any dividends for the year ended December 31, 2025[32] - The board has decided not to declare any final dividend for the fiscal year 2025, consistent with the previous year[106] - The average number of ordinary shares outstanding increased to 557,077,333 in 2025 from 532,837,181 in 2024, which may impact earnings per share calculations[33] Regulatory and Compliance - International Financial Reporting Standard (IFRS) 18 introduces new presentation requirements for income statements, categorizing all income and expenses into five categories: operating, investing, financing, income tax, and discontinued operations[11] - The amendments to IFRS 9 and IFRS 7 are expected to have no significant impact on the group's financial statements[14][15][16] - The company has established an audit committee to oversee financial reporting processes and compliance with legal regulations[112] - The company has adopted the corporate governance code to ensure transparency, accountability, and independence[109] Strategic Initiatives - The company plans to enhance the capacity of non-surgical medical beauty services, focusing on the introduction of new technologies and equipment to meet consumer demand[42] - The company aims to launch more products and services tailored to different skin types and age groups to meet personalized consumer needs[42] - The company is optimizing its sales channels by leveraging internet platforms, social media, and partnerships with third-party platforms to enhance market reach and operational efficiency[45] - The company plans to focus on the sales of non-surgical medical beauty devices, increasing investment in technology and research, and expanding the geographical coverage of medical beauty service institutions[105] Market Conditions - The medical beauty industry in China is still in a phase of expansion and adjustment, with non-surgical beauty services being the main growth driver, particularly anti-aging projects[105] - The company faces risks including medical liability insurance, brand recognition, and exchange rate fluctuations affecting its operations[53]

（於開曼群島註冊成立的有限公司） （股份代號：2135） 董事會會議日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Raily Aesthetic Medicine International Holdings Limited 瑞麗醫美國際控股有限公司 傅海曙先生 中華人民共和國杭州，二零二六年三月十六日 瑞麗醫美國際控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」）董事（「董 事」）會（「董事會」）謹此宣佈，董事會會議將於二零二六年三月二十七日（星期五） 舉行，以（其中包括）考慮及批准本集團截至二零二五年十二月三十一日止年度之 經審核年度業績及其刊發，以及考慮宣派、建議或支付股息（如有）。 承董事會命 瑞麗醫美國際控股有限公司 主席兼執行董事 於本公告日期，董事會包括執行董事傅海曙先生、宋建良先生及王瀛先生；以及獨 立非執行董事曹德全先生、楊小芬女士及劉騰先生。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Raily Aesthetic Medicine International Holdings Limited 瑞麗醫美國際控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2135） 盈利預告 1 董事會認為，預期截至2025年12月31日止年度業績改善乃主要由於2024年錄得一次 性減值虧損，而2025年並無此項。本公司整體業務利潤率的提升亦對2025年業績的 改善有所貢獻。 本公司仍在落實本集團截至2025年12月31日止年度之綜合年度業績。本公告所載 資料僅依據對本集團截至2025年12月31日止年度的未經審核管理賬目的初步評估 及董事會目前可獲得之資料而得出，有關資料未經本公司核數師審核，亦未經本 公司審核委員會審閱，於必要時會予以修訂及調整。有關本集團財務資料的詳情 將於本公司截至2025年12月31日止年度的年度業績公告中披露，該公告預期將根 據上市規則於2026年3月底前刊發。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 足夠公眾持股量的確認(註4) 公司名稱: 瑞麗醫美國際控股有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02135 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 1,000,000,000 | | USD | | 0.05 USD | | 50,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 1,000,000,000 | USD | | 0.05 USD | ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 瑞麗醫美國際控股有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02135 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.05 USD | | 50,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 1,000,000,000 | USD | | 0.05 USD | | 50,000,000 | ...

Group 1 - The "Top Ten Outstanding Figures in the Medical Aesthetics Industry for 2025" list was announced by Rui Finance, highlighting industry leaders based on professional ability, performance, and influence [2] - Fu Haishu, Chairman of Ruili Medical Aesthetics, was selected for this prestigious list, indicating his significant impact in the medical aesthetics sector [2] - The evaluation criteria for the list included comprehensive assessments of professional skills, performance metrics, and industry influence [2] Group 2 - Fu Haishu graduated from Shanghai Medical University in July 1999, specializing in clinical medicine, and has over 16 years of experience in the medical aesthetics industry [3] - He is the founder, executive director, and chairman of the board of the group, responsible for overall management, decision-making, and strategic planning [3] - In 2025, under Fu Haishu's leadership, the group aims to deepen its presence in the Yangtze River Delta and Northeast regions, focusing on "technology upgrades, genuine product assurance, and public welfare image" while extending into upstream medical aesthetics equipment research and manufacturing [3]

Core Viewpoint - Recently, Ruiley Medical Beauty announced a subscription agreement with Miao Shi Aesthetics, investors, shareholders, and the target company, Laili Medical Beauty, indicating a strategic move to expand its business in Hong Kong and enhance financial performance through synergies [1] Group 1: Subscription Agreement Details - Ruiley Medical Beauty's indirect non-wholly owned subsidiary will subscribe for 170,000 shares of Laili Medical Beauty for HKD 2.55 million, acquiring a 51.0% stake [1] - Bifu Limited will subscribe for 63,300 shares for HKD 0.95 million, holding a 19.0% stake, while Miao Shi Aesthetics will hold a 30.0% stake [1] - Following the completion of the agreement, Laili Medical Beauty will become an indirect non-wholly owned subsidiary of Ruiley Medical Beauty, with its financial performance consolidated into the group’s accounts [1] Group 2: Business Strategy and Expectations - The board believes that the subscription aligns with the group's business expansion strategy and presents an opportunity to enhance operations in Hong Kong [1] - The expected improvement in the operational and financial performance of the target company could provide potential investment returns for the group [1]

Core Viewpoint - 瑞丽医美 has entered into a subscription agreement to acquire shares in 莱丽医美有限公司, which will enhance its business operations in Hong Kong and provide potential investment returns [1][2] Group 1: Subscription Agreement Details - 瑞丽医美 will issue a total of 170,000 shares to the first investor 瑞丽美学有限公司 at a subscription price of 2.55 million HKD and 63,300 shares to the second investor 比夫有限公司 at a subscription price of 950,000 HKD [1] - After the completion of the agreement, the shareholding will be distributed as follows: 缪诗美学 will hold 30.0%, the first investor will hold 51.0%, and the second investor will hold 19.0% of the target company [1] - The target company 莱丽医美有限公司 will become an indirect non-wholly owned subsidiary of 瑞丽医美, and its financial performance will be consolidated into the group’s accounts post-completion [1] Group 2: Strategic Rationale - The board believes that the subscription aligns with the group’s business expansion strategy, particularly in enhancing its presence in the Hong Kong market [2] - The subscription is viewed as a unique opportunity to promote the brand and provide beauty services to potential customers, creating synergies with existing operations [2] - The operational and financial performance of the target company is expected to improve once it commences beauty services in Hong Kong, potentially leading to investment returns for the group [2]